Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Inclusion Criteria: * Written informed consent * At least 18 years old * Histologically- or cytologically-confirmed diagnosis of Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLC (or for Phase I only, advanced solid tumor for which there is no standard therapy or for whom paclitaxel is standard therapy). * No prior systemic first-line therapy for advanced disease * Measurable disease * ECOG performance status of 0 or 1 * Life expectancy of at least 12 weeks. * Able to swallow and retain oral medication * Adequate organ system function (hematological, renal, and hepatic) * Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception Exclusion Criteria: * Active malignancy or any malignancy in the 3 years prior to first dose of study drug other than NSCLC (or for Phase I, other than the primary solid tumor) * CNS metastases or leptomeningeal carcinomatosis, except for asymptomatic, previously treated CNS metastases * Clinically significant gastrointestinal abnormalities * Prolongation of corrected QT interval (QTc) \> 480 msecs * History of any one or more cardiovascular conditions within the past 6 months prior to randomization * Poorly controlled hypertension * History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months * Major surgery or trauma within 28 days or any non-healing wound, fracture, or ulcer * Evidence of active bleeding or bleeding diathesis * Recent hemoptysis * Endobronchial lesions and/or lesions infiltrating major pulmonary vessels * Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures * Use of any prohibited medication * Use of an investigational agent within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug * Ongoing toxicity from prior anti-cancer therapy that is \>Grade 1 and/or that is progressing in severity except alopecia * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib, paclitaxel, and/or carboplatin.